[Possibilities and limitations of selective beta 1 adrenergic receptor blockade in clinical practice].
The use of various doses of metoprolol (spesicor, Leiras, Finland), a selective beta 1-adrenoblocker, in patients with CHD combined with clinical or instrumentally detectable symptoms of bronchial asthma or stage I-II essential hypertension with angina pectoris of I-II functional classes, has shown that metoprolol cardioselective blockade is a relative phenomenon which has definite correlation with a dose, duration of therapy, and the initial status of the bronchopulmonary system. An antianginal effect was observed in 68.5% of patients, an antihypertensive effect--in 71.3%, side-effects--in 6.4%.
Ol'binskaia
L I
LI
Vartanova
O A
OA
Sinopal'nikov
A I
AI
Alekseev
V G
VG
Logunov
O V
OV
D000328:Adult; D000368:Aged; D001919:Bradycardia / Q000139:chemically induced; D001980:Bronchi / Q000187:drug effects; D001986:Bronchial Spasm / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged
D008790:Metoprolol
Vozmozhnosti i predely selektivnoi blokady beta 1-adreno-retseptorov v klinicheskoĭ praktike.